Company profile · free preview

Entera Bio

ENTX · Updated 10/25/2026

Revenue

$42000

Fiscal 2025

Net income

(11.4M)

Fiscal 2025

Free cash flow

(7.5M)

Fiscal 2025

Net cash / (debt)

—

Fiscal 2025

Five-year financials

Fiscal year20252024202320222021
Revenue$42000$181000$0$134000$571000
Net income(11.4M)(9.5M)(8.9M)(13.1M)(12.2M)
Diluted EPS—————
Operating cash flow(7.4M)(6.8M)(7.3M)(12.5M)(9.1M)
Free cash flow(7.5M)(6.8M)(7.3M)(12.5M)(9.1M)
Cash$7.1M$8.7M$11.0M$12.3M$24.9M
Total debt—————

Where the cash went

Cumulative, fiscal 2021–2025, straight from the reported cash-flow statements.

Reinvested in capex

—

of operating cash flow

Returned to owners

—

of free cash flow (buybacks + dividends)

Diluted share count

—

change 2021–2025

Capital expenditure $191000Bar width = share of $191000 (spending exceeded operating cash flow)
Operating cash flow($43.1M)
Capital expenditure($191000)
Free cash flow($43.3M)
Share buybacks—
Dividends paid—
Acquisitions (net)—
Net debt issued / (repaid)—
Stock-based compensation (non-cash)—

"—" means a year didn't report that line, so no total is shown rather than an estimate.

SEC filings

No filings stored yet.

Ask anything about Entera Bio's filings

"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.

Start researching free

More companies